Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (June 2026)
17 slides from Bayer's technical presentation, June 2026
Slide 1: Presentation provided in response to unsolicited request
The following presentation is being provided in response to your unsolicited request. This content was presented in June 2026 at the Endocrine Society Annual Meeting. The authors of this content are: Jill Liss, Lisa C. Larkin, JoAnn V. Pinkerton*, Kesley Martin, Gina Woods, Barbara Dehn, Chrisandra
Slide 2: Views expressed are those of the faculty
The views expressed in this educational program are those of the faculty and do not necessarily represent the views of the Endocrine Society.
Slide 3: Views expressed are those of the faculty
The views expressed in this educational program are those of the faculty and do not necessarily represent the views of the Endocrine Society.
Slide 4: Modified Delphi Consensus on Non-Hormone Therapy for Moderate-to-Severe VMS: MenoMEC Tool
MODIFIED DELPHI CONSENSUS ON NON- H O R M O N E T H E R A P Y F O R M O D E R AT E - T O - S E V E R E VA S O M O T O R S Y M P T O M S : T O WA R D A M E N O PA U S E M E D I C A L ELIGIBILITY CRITERIA (MENOMEC) TOOL L I S S J , L A R K I N L C , P I N K E R T O N J V, M A R T I N K , W O O D S G ,
Slide 5: Disclosures
DISCLOSURES All authors received financial support from Bayer to conduct this study. The views expressed in this educational program are those of the faculty and do not necessarily represent the views of the Endocrine Society nor those of Bayer. The views expressed in this educational program are th
Slide 6: Background & Rationale
BACKGROUND & RATIONALE • Menopausal vasomotor symptoms (VMS; also known as hot flashes or night sweats) are common and disruptive • Hormone therapy (HT) is first-line, but contraindicated or declined in many women • Non-hormone therapy (NHT) options exist, but US comorbidity-specific guidance is lac
Slide 7: Objectives
OBJECTIVES • E S TA B L I S H C O N S E N S U S R E C O M M E N D AT I O N S O N T H E U S E O F N H T F O R M O D E R AT E - T O - SEVERE VMS • D E V E L O P C O M O R B I D I T Y- S P E C I F I C H T V S . N H T GUIDANCE • C R E AT E A M E N O M E C T O O L F O R W O M E N ’ S H E A LT H C A R E P
Slide 8: Study Design
STUDY DESIGN Methods Consensus Process • Modified Delphi panel with 15 • In-person meeting (Boston, March multidisciplinary experts 2025) for non-consensus items • Systematic review of US • Three follow-up discussions to guidelines (2014–2024) refine recommendations • Online survey with 9-point Like
Slide 9: Study Timeline
STUDY TIMELINE January 2025 March 2025 Sept 2025 – April 2025 March 2026 May 2026 Tool Finalization MenoMEC clinical tool In-Person Meeting 2 hr consensus discussion Follow-up Discussions Refine decision-support tool In-Person Meeting 8 hr consensus discussion Online Survey 60 min, pre-meeting The v
Slide 10: Results
Primary Menopausal Recommended First-Line Alternative or Second- Symptom Treatment Line Treatment SSRI/SNRI (e.g., RESULTS VMS; also known as hot flashes or night sweats NK-receptor antagonists venlafaxine, paroxetine 7.5mg daily), Gabapentin, Oxybutynin Gabapentin (nighttime • HT remains first-line
Slide 11: Comorbidity-Specific Guidance
COMORBIDITY-SPECIFIC GUIDANCE • Therapies rated: HT (transdermal/oral), approved NHT Rating (NK-receptor antagonist, paroxetine), off-label NHT 1 No restrictions (gabapentin, oxybutynin, SSRIs/SNRIs) • 13 comorbid conditions: age, smoking, 2 Benefits > risks ASCVD/PREVENT score, CVD, metabolic, brea
Slide 12: Medical Eligibility Criteria Guidance Summary
Medical Eligibility Criteria Guidance Summary: Therapies for Vasomotor Symptoms of Menopause (USA) The recommendations in this document are based on the best available evidence and expert opinion; all treatment decisions warrant a discussion with the treating clinician and any relevant specialties w
Slide 13: Medical Eligibility Criteria Guidance Summary
Medical Eligibility Criteria Guidance Summary: Therapies for Vasomotor Symptoms of Menopause (USA) The recommendations in this document are based on the best available evidence and expert opinion; all treatment decisions warrant a discussion with the treating clinician and any relevant specialties w
Slide 14: Medical Eligibility Criteria Guidance Summary
Notes Hormone Non-Hormone Therapy Please refer to footnotes a,b Therapya,b On-Label On-Label Off-Label Fezolineta elinzanetant, cThis is applicable to women >65 years. Cognitive decline was fezolinetant) Paroxetine (Brisdelle®) Elinzaneta Neurokinin Antagonist Other SSRIs / SNRIsd Therapies Receptor
Slide 15: Medical Eligibility Criteria Guidance Summary
Notes Hormone Non-Hormone Therapy Please refer to footnotes a,b Therapya,b On-Label On-Label Off-Label Therapies (NKT: elinzanetant, fezolinetant) cThis is applicable to women >65 years. Cognitive Neurokinin Antagonist Receptor Paroxetine (Brisdelle®) Other SSRIs / SNRIsd decline was reported with o
Slide 16: MenoMEC Tool & Clinical Implications
MENOMEC TOOL & CLINICAL IMPLICATIONS • Decision-support tool for choosing among VMS therapies • Modeled after WHO MEC for contraception — familiar framework • Individualizes care by patient comorbidities, with focus on cardiovascular disease, cancer, hepatic disease, and thrombosis • Will be availab
Slide 17: Thank You
THANK YOU J V P 9 U @ U VA H E A LT H . O R G The views expressed in this educational program are those of the faculty and do not necessarily represent the views of the Endocrine Society.